Efficient Serotype-Dependent Release of Functional Vector into the Culture Medium During Adeno-Associated Virus Manufacturing
- 1 October 2010
- journal article
- research article
- Published by Mary Ann Liebert Inc in Human Gene Therapy
- Vol. 21 (10), 1251-1257
- https://doi.org/10.1089/hum.2010.107
Abstract
Vectors based on adeno-associated virus (AAV) are the subject of increasing interest as research tools and agents for in vivo gene therapy. A current limitation on the technology is the versatile and scalable manufacturing of vector. On the basis of experience with AAV2-based vectors, which remain strongly cell associated, AAV vector particles are commonly harvested from cell lysates, and must be extensively purified for use. We report here that vectors based on other AAV serotypes, including AAV1, AAV8, and AAV9, are found in abundance in, and can be harvested from, the medium of production cultures carried out with or without serum. For AAV2, this difference in compartmentalization is largely due to the affinity of the AAV2 particle for heparin, because an AAV2 variant in which the heparin-binding motif has been ablated gives higher yields and is efficiently released from cells. Vector particles isolated from the culture medium appear to be functionally equivalent to those purified from cell lysates in terms of transduction efficiency in vitro and in vivo, immunogenicity, and tissue tropism. Our findings will directly lead to methods for increasing vector yields and simplifying production processes for AAV vectors, which should facilitate laboratory-scale preparation and large-scale manufacture.This publication has 21 references indexed in Scilit:
- Rapid, Simple, and Versatile Manufacturing of Recombinant Adeno-Associated Viral Vectors at ScaleHuman Gene Therapy, 2010
- A New Genetic Vaccine Platform Based on an Adeno-Associated Virus Isolated from a Rhesus MacaqueJournal of Virology, 2009
- Naturally occurring singleton residues in AAV capsid impact vector performance and illustrate structural constraintsGene Therapy, 2009
- Treatment of Leber Congenital Amaurosis Due toRPE65Mutations by Ocular Subretinal Injection of Adeno-Associated Virus Gene Vector: Short-Term Results of a Phase I TrialHuman Gene Therapy, 2008
- Safety and Efficacy of Gene Transfer for Leber's Congenital AmaurosisThe New England Journal of Medicine, 2008
- Effect of Gene Therapy on Visual Function in Leber's Congenital AmaurosisThe New England Journal of Medicine, 2008
- Recombinant adeno-associated virus vectors induce functionally impaired transgene product–specific CD8+ T cells in miceJCI Insight, 2007
- Vaccines Based on Novel Adeno-Associated Virus Vectors Elicit Aberrant CD8+T-Cell Responses in MiceJournal of Virology, 2007
- Single Amino Acid Changes Can Influence Titer, Heparin Binding, and Tissue Tropism in Different Adeno-Associated Virus SerotypesJournal of Virology, 2006
- Robust systemic transduction with AAV9 vectors in mice: efficient global cardiac gene transfer superior to that of AAV8Molecular Therapy, 2006